RespireRx Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
RSPI RespireRx Pharmaceuticals Inc
CARV Carver Bancorp Inc
$NQDMASIA4050LMGBP Nasdaq DM Asia Travel and Leisure La
ENLC EnLink Midstream LLC
MNTX Manitex International Inc
ACMR ACM Research Inc
DEA Easterly Government Properties Inc
NBSTU Newbury Street Acquisition Corp
UPS United Parcel Service Inc
BOLT Bolt Biotherapeutics Inc
Go

Health Care : Pharmaceuticals | Small Cap Value
Company profile

RespireRx Pharmaceuticals Inc. is engaged in the discovery, development and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. The Company is developing treatment options that address obstructive sleep apnea (OSA), attention deficit hyperactivity disorder (ADHD) epilepsy, chronic pain, including inflammatory and neuropathic pain, and recovery from spinal cord injury (SCI), which are conditions that affect people. Its pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the nervous system’s endogenous cannabinoid receptors. Its neuromodulators platform consists of two programs: its AMPAkines program, which includes compounds that are positive allosteric modulators (PAMs) of AMPA-type glutamate receptors to promote neuronal function and GABAkines program, including compounds that are PAMs of GABAA receptors.

The symbol you entered, COR, changed to RSPI.

Closing Price
$0.0128
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.0128
Day's Low
0.0128
Volume
(Light)
Volume:
2,100

10-day average volume:
53,081
2,100

Display:

Providers:

UpdateCancel
6 providers
January 24, 2022
RespireRx Pharmaceuticals Inc. Announces Publication of a Manuscript Describing Its Newest Neuromodulator for Pharmacoresistant Epilepsy and Chronic Pain

RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce...(Globe Newswire)

December 20, 2021
Life Sciences Companies Investor Presentations Now Available for On-Demand Viewing

Virtual Investor Conferences, the leading proprietary investor conference series, today announced that the presentations from the December 16th Life Sciences Virtual Investor Conference are now available for on-demand viewing. (PR Newswire)

December 14, 2021
RespireRx Pharmaceuticals Inc. to Present at Upcoming Virtual Life Sciences Investor Conference and Biotech Showcase(TM)

RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"), with a mission to discover and develop innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that...(Globe Newswire)

December 09, 2021
Life Sciences Virtual Investor Conference: Company Executives Present Live December 16th

Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for its quarterly event for public and private companies, investors, and industry professionals from around the world. This day-long virtual event...(PR Newswire)

December 06, 2021
RespireRx Pharmaceuticals Inc. Announces Publication of Review Article Describing Advances in the Discovery, Development and Commercialization of GABAkines, Including KRM-II-81

RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce...(Globe Newswire)

November 30, 2021
RespireRx Pharmaceuticals Inc. Announces Publication of Book Chapter Describing Novel Analgesic Properties of KRM-II-81

RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce...(Globe Newswire)

November 29, 2021
RespireRx Pharmaceuticals Inc. Announces Publication of Preclinical Results Supporting the Use of AMPAkines in the Treatment of Human Spinal Cord Injury

RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) ("RespireRx" or the "Company"), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce...(Globe Newswire)

November 22, 2021
RespireRx Pharmaceuticals Inc. Announces CEO's OTC Venture Market Podcast

RespireRx Pharmaceuticals Inc. (OTCQB: RSPI), ("RespireRx" or the "Company") a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce...(Globe Newswire)

November 04, 2021
RespireRx Pharmaceuticals Inc. Announces Video Interview of CFO

RespireRx Pharmaceuticals Inc. (OTCQB: RSPI), ("RespireRx" or the "Company") a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.